Navigation Links
NW Bio Activates Second Site in DCVax-Direct Phase I/II Trial
Date:9/24/2013

pan>-Houston, where the first DCVax-Direct patients have been enrolled, while other patients are going through assessment for eligibility.  These two prominent centers bring a very strong combined patient flow, which will help accelerate the enrollment of the trial.  In addition, other trial sites in the US and Europe are in various stages of preparation.

The primary endpoint of the trial for measuring the efficacy of DCVax-Direct is tumor regression.  Since regression may be seen within just a few months of treatment, and since this Phase I/II trial is an open label, unblinded trial, it is anticipated that some initial results from the first patients may be seen before year end.  

Dr. Marnix Bosch, Chief Technical Officer of NW Bio observed,  "It is a tremendous honor for us to work with these two world-class institutions for this trial.  The teams at both of these medical centers are bringing a high level of dedication to this groundbreaking study, which may help create better chances of success.  We appreciate the expertise and motivation that we have experienced through the entire training and treatment processes, and look forward to working with both teams on an ongoing basis."

Dr. Mark Roh, President of MD Anderson-Orlando, states,  "We are very excited to be joining this clinical trial to further advance cancer care and possibly expand treatment options to cancer patients.  Our oncologists and staff are dedicated to providing our patients with every opportunity to fight their disease, and being a part of this trial will give additional research options to the brave men and women who walk through our doors."

About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developin
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Baylor University Medical Center activates Allscripts electronic health record system
2. UBM Medica US Medical Diagnostic Game Makes Second Appearance on ConsultantLive
3. Apollo Medical Holdings Reports Record Fiscal 2014 Second Quarter Results
4. Access Pharmaceuticals Awarded Second European Patent for MuGard
5. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
6. China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2013 Financial Results
7. ConvaTec Announces 2013 Second Quarter Earnings Call
8. PRN Physician Recommended Nutriceuticals Selected for the Second Consecutive Year to the Inc. 500
9. 5000 List of Fastest-Growing Privately Held Companies
10. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
11. ULURU Inc. Reports Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will ... the Australian and New Zealand Forensic Science Society,s ... Sciences in Adelaide, Australia . ... concerning the advancements that hyperspectral imaging can bring ... Jeffrey Beckstead , Director of Product Development at ...
(Date:8/29/2014)... Aug. 29, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the CL ... on Tuesday, September 9, 2014 at 12:30 p.m. ET. ... Place Hotel in New York City ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... clinical study to evaluate multiple ascending doses of NKTR-181, ... in development as a once- or twice-daily oral tablet ... to address the abuse liability and serious central nervous ...
... 8, 2011 Reportlinker.com announces that a ... its catalogue: Global Intravenous ... http://www.reportlinker.com/p0611078/Global-Intravenous-IV-Solutions-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_E This report analyzes ... in US$ Million. The report provides separate ...
Cached Medicine Technology:Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 2Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 3Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 4Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 5Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain 6Global Intravenous (IV) Solutions Industry 2Global Intravenous (IV) Solutions Industry 3Global Intravenous (IV) Solutions Industry 4Global Intravenous (IV) Solutions Industry 5Global Intravenous (IV) Solutions Industry 6Global Intravenous (IV) Solutions Industry 7Global Intravenous (IV) Solutions Industry 8
(Date:8/30/2014)... “In 2013, a vehicle crash occurred every 5 ... a recently released article on 2013 Washington auto accident ... auto accident every 12 minutes, and a motorcyclist is involved ... the 2013 statistics, between now and this same time tomorrow, ... of an auto accident is real and impending - five ...
(Date:8/30/2014)... 30, 2014 Barton Associates, an industry ... locum tenens company , announces a new office location ... Barton Associates is headquartered in Peabody, MA, with additional ... and Jupiter, FL. , Barton Associates decided ... demand for healthcare providers. The United States is in ...
(Date:8/30/2014)... Saturday 30 August 2014: The first multidisciplinary recommendations ... acute coronary syndromes (ACS) are published today in ... was written jointly by the European Heart Rhythm ... and the European Association of Percutaneous Cardiovascular Interventions ... Bulent Gorenek (Turkey), chairperson of the task force, ...
(Date:8/30/2014)... The therapeutic benefit of revascularisation in coronary artery ... revascularisation guidelines presented at ESC Congress by joint ... the European Society of Cardiology (ESC) and Professor ... Cardio-Thoracic Surgery (EACTS). The joint guidelines are published ... (1), on the ESC Website (2), in EuroIntervention ...
(Date:8/29/2014)... 30, 2014 AGH Healthy Happenings, a ... Doctors in Delaware at Atlantic General Hospital, are ... services. In addition to no-cost blood pressure screenings at ... aid care at local sports tournaments. , In ... staff provide free disease management and falls prevention workshops ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 3Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 3
... Strictly embargoed until: 00.01 GMT, Friday, 12 October, ... world,s,maternal mortality ratio (the number of maternal deaths per ... Development Goal (MDG),5, which aims to improve maternal health ... While an annual decline of 5.5 per cent in ...
... Calif., Oct. 11 Each year, more than,90,000 ... of gynecological cancer.,Although the overall death rate for ... cancer has increased slightly. Dr. Stan Wasbin, ... provides an overview of gynecological,cancer, stressing the importance ...
... little,cooler for the patients at Children,s National Medical Center, ... will make their annual,visit. The team will also launch ... Caps., Courage Caps are team-issued and branded hats ... games and online at NHL.com, with,100 percent of the ...
... Cancer researchers have long worked to understand why some ... to stop the production of testosterone and other androgens ... detected that androgen-synthesizing proteins are present within cancer cells, ... to produce their own androgens. , The presence ...
... School of Medicine have found that professional welders who ... at risk for loss of sense of smell. ... the first study to clearly demonstrate that welders who ... at risk for damaging their sense of smell, says ...
... 11 Six earthbound "angels" who have,brightened the lives ... Shield of Michigan. The Caring for Children Angel ... children,s lives. The awards have been,sponsored annually by the ... be honored at a Friday, Nov. 9 reception and ...
Cached Medicine News:Health News:Maternal Mortality Declining in Middle-income Countries; Women Still Die in Pregnancy and Childbirth in Low-income Countries 2Health News:Maternal Mortality Declining in Middle-income Countries; Women Still Die in Pregnancy and Childbirth in Low-income Countries 3Health News:The Silent Killer, Ovarian Cancer on Your Cancer Today (TM) 2Health News:New research may show why some prostate cancer recurs after treatment 2Health News:New research may show why some prostate cancer recurs after treatment 3Health News:Penn study suggests professional welders at risk for loss of sense of smell 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 2Health News:Blue Cross Blue Shield of Michigan Salutes Six 'Angels' 3
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 45 degrees....
Titanium. 0.12 mm 1 x 2 teeth with 6 mm platform and 2.0 mm angled tips. Flat serrated handle, dull finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
Narrow 4 mm long smooth platform. Serrated handle with polished finish....
Medicine Products: